When Was Sapropterin First Used in Clinical Trials?
Sapropterin, marketed as Kuvan, entered its first clinical application in Phase 1 trials in 2002. These early studies tested safety and pharmacokinetics in healthy volunteers and patients with phenylketonuria (PKU).[1]
What Led to Its Initial Clinical Testing?
Researchers at BioMarin Pharmaceutical began developing sapropterin (tetrahydrobiopterin or BH4) after preclinical work showed it could lower blood phenylalanine levels in PKU patients. The first human dosing occurred in 2002 under an Investigational New Drug (IND) application filed with the FDA.[2][3]
Key Milestones After First Clinical Use
- 2004-2005: Phase 2 and Phase 3 trials confirmed efficacy, with positive data presented at medical conferences.
- 2007: FDA approval for PKU treatment in patients aged 4 and older.
- 2018: Expanded approval for infants aged 1 month and older.[4]
How Does Sapropterin's Timeline Compare to Similar Drugs?
Unlike older PKU treatments like phenylalanine-restricted diets (used since the 1950s), sapropterin was the first pharmacologic option. Competitors like pegvaliase (Palynziq, approved 2018) followed years later.[5]
[1]: ClinicalTrials.gov - First sapropterin trial (NCT00056267)
[2]: BioMarin annual reports (2002 IND filing)
[3]: FDA approval history
[4]: FDA label updates
[5]: DrugPatentWatch.com - Sapropterin patents and timeline